Related Experiment Video
Updated: Oct 19, 2026
Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
Published on: June 14, 2016
Serum mucin antigen (CASA) as a marker of amiodarone-induced pulmonary toxicity
P L Devine1, W J Siebert, S L Morton
1Department of Obstetrics & Gynaecology, University of Queensland, Brisbane, Australia.
Abstract:
Amiodarone is used to treat life-threatening cardiac arrhythmias. Amiodarone-induced pulmonary toxicity (APT) can be difficult to diagnose. APT may result in increased mucus production and mucin expression. Thus, serum mucin-1 was evaluated as a marker for amiodarone-induced pulmonary toxicity. Concentrations of mucin-1 in peripheral blood were determined using cancer-associated serum antigen (CASA) assay in patients taking amiodarone. Eight of ten patients who developed major amiodarone toxicity had high serum CASA levels. Patients with toxicity had a significantly higher mean rank CASA concentration compared with those without major toxicity. CASA shows potential as a marker for amiodarone-induced toxicity, particularly pulmonary toxicity.
Insights
Serum mucin-1, measured by cancer-associated serum antigen (CASA) assay, shows potential for diagnosing amiodarone-induced pulmonary toxicity (APT). Elevated CASA levels were observed in patients experiencing amiodarone toxicity, aiding in early detection.
Area of Science:
- Cardiology
- Pulmonology
- Biomarker Discovery
Background:
- Amiodarone is a critical treatment for life-threatening cardiac arrhythmias.
- Amiodarone-induced pulmonary toxicity (APT) presents diagnostic challenges.
- Increased mucus production and mucin expression are associated with APT.
Purpose of the Study:
- To evaluate serum mucin-1 as a potential diagnostic marker for amiodarone-induced pulmonary toxicity (APT).
- To assess the utility of cancer-associated serum antigen (CASA) assay in identifying APT.
Main Methods:
- Serum mucin-1 concentrations were measured using the cancer-associated serum antigen (CASA) assay.
- CASA levels were analyzed in patients undergoing amiodarone treatment, comparing those with and without major toxicity.
Main Results:
- Eight out of ten patients with major amiodarone toxicity exhibited high serum CASA levels.
- Patients with toxicity demonstrated significantly higher mean rank CASA concentrations compared to those without toxicity.
Conclusions:
- Serum CASA shows promise as a reliable biomarker for detecting amiodarone-induced toxicity, especially pulmonary complications.
- This finding could lead to improved diagnostic strategies for APT.
